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In vivo therapeutic efficacy of frog 
skin-derived peptides against 
Pseudomonas aeruginosa-induced 
pulmonary infection
Chen Chen  1, Maria Luisa Mangoni2 & Y. Peter Di  1
Pseudomonas aeruginosa is an opportunistic and frequently drug-resistant pulmonary pathogen 
especially in cystic fibrosis sufferers. Recently, the frog skin-derived antimicrobial peptide (AMP) 
Esc(1–21) and its diastereomer Esc(1–21)-1c were found to possess potent in vitro antipseudomonal 
activity. Here, they were first shown to preserve the barrier integrity of airway epithelial cells better 
than the human AMP LL-37. Furthermore, Esc(1–21)-1c was more efficacious than Esc(1–21) and LL-37 
in protecting host from pulmonary bacterial infection after a single intra-tracheal instillation at a very 
low dosage of 0.1 mg/kg. The protection was evidenced by 2-log reduction of lung bacterial burden 
and was accompanied by less leukocytes recruitment and attenuated inflammatory response. In 
addition, the diastereomer was more efficient in reducing the systemic dissemination of bacterial cells. 
Importantly, in contrast to what reported for other AMPs, the peptide was administered at 2 hours after 
bacterial challenge to better reflect the real life infectious conditions. To the best of our knowledge, 
this is also the first study investigating the effect of AMPs on airway-epithelia associated genes upon 
administration to infected lungs. Overall, our data highly support advanced preclinical studies for the 
development of Esc(1–21)-1c as an efficacious therapeutic alternative against pulmonary P. aeruginosa 
infections.
Multidrug-resistant (MDR) bacterial infections represent a serious life-threat causing almost 50,000 deaths per 
year in Europe and in the US; and this number is expected to grow up to tenfold by 2050, killing more than can-
cer1, 2. In particular, pulmonary infections due to the Gram-negative bacterium Pseudomonas aeruginosa remain 
one of the major cause of morbidity and mortality3, either in intensive care units or in ventilated patients, as well 
as in cystic fibrosis (CF) sufferers, complicating therapy in the CF airways4–7. In parallel, the decrease in the phar-
maceutical industry research pipeline for novel antimicrobial agents during the last three decades has resulted in 
an urgent need for the discovery of new strategies to address the vital problems of infectious diseases8, 9. Naturally 
occurring antimicrobial peptides (AMPs) or their derivatives stand for an appealing source for the generation of 
new therapeutics9–16. AMPs are ubiquitous in nature and act as the first line of defence against invading microor-
ganisms17, 18. Although human lung epithelial cells produce AMPs (e.g. defensins and the cathelicidins LL-37)19, 20, 
most of them are present at very low concentrations and are salt-sensitive in vitro making it difficult for them to 
be active in the abnormally low pH and high-salt environment existing at the apical side of CF epithelial cells21–23. 
A promising therapeutic approach to defeat P. aeruginosa lung infections would be to exogenously apply AMPs in 
the lung environment. We recently identified a short-sized (21 amino acids long) derivative of the frog-skin AMP 
esculentin-1a, named Esculentin-1a(1–21)NH2 [GIFSKLAGKKIKNLLISGLKG-NH2, Esc(1–21)]24, 25, with the 
following attractive features: (i) a potent and rapid killing kinetics against both planktonic and biofilms forms of 
P. aeruginosa strains, with a pronounced membrane-perturbing activity as a plausible mode of action26. This is a 
highly non-specific mechanism which limits the induction of resistance compared to the highly selective conven-
tional antibiotics e.g. tobramycin and ciprofloxacin that would no longer be able to recognize their specific and 
single target, after mutation27; (ii) the ability to preserve antimicrobial activity at high ionic strength, in contrast 
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with the majority of AMPs of mammalian origin28; (iii) the ability to detoxify, in vitro, P. aeruginosa lipopolysac-
charide (LPS), by inhibiting the release of TNF-α from LPS-activated macrophages28.
In addition, a diastereomer of Esc(1–21), named Esc(1–21)-1c, containing only two d-amino acid substitu-
tions at the C-terminal region (dLeu14 and dSer17) was lately synthesized and found to be significantly more stable 
than the corresponding all-L peptide and less susceptible to enzymatic degradation (i.e. human and bacterial 
elastases)29; less toxic towards mammalian cells; more active against P. aeruginosa biofilms and more efficient in 
stimulating bronchial cells migration and presumably in restoring the integrity of an injured bronchial epithe-
lium, a property which is not shown by any traditional antibiotic28, 30.
Even though AMPs are under investigation as novel therapeutics to defeat microbial infections, only a few 
studies have been reported to date on their antibacterial activity in the lungs of animal models of P. aeruginosa 
pneumonia31, 32. Remarkably, as learned from literature, when locally applied via intra-nasal or intra-tracheal 
route in murine models of acute lung infection, they are generally administered after a short time interval 
(5–15 min) from bacterial infection33, 34. Furthermore, to the best of our knowledge, no studies have been accom-
plished by the effect(s) of AMPs on the airway epithelial gene expression after P. aeruginosa-induced respiratory 
infection.
Taking into account the attractive properties of the two esculentin-derived peptides, we first evaluated their 
outcome on the bronchial epithelium permeability followed by their therapeutic efficacy in murine models of 
acute Pseudomonas lung infections, upon intra-tracheal instillation. Their effects on the expression of inflam-
mation associated genes were also investigated. Overall, the results of our experiments have pointed out a higher 
in vivo antipseudomonal activity of the diastereomer Esc(1–21)-1c than its all-l counterpart without provoking 
any noticeable inflammation or damage at the lung level. Importantly, our work is the first demonstration of a 
frog-skin derived AMP to significantly promote lung clearance of P. aeruginosa when administered in a sin-
gle dose at 2 hours after infection. The designed diastereomer demonstrated a higher antibacterial activity than 
the mammalian AMP LL-37, as well as a comparable potency to that of the clinically used colistin peptide35, 36, 
whose antibacterial activity is exerted through binding to LPS, the major component of the outer membrane of 
Gram-negative bacteria.
Hence, our data imply the diastereomer Esc(1–21)-1c as an attractive peptide for the development of future 
therapy for effective treatments of Pseudomonas-induced lung infections.
Results
Effect of peptides on the lung epithelial tight junction permeability. It was previously demon-
strated that Esc(1–21) has a strong in vitro antipseudomonal activity, with a minimal inhibitory concentration 
(MIC) of 4 μM26. Before performing in vivo studies, the effect of the two esculentin derivatives on the integrity of 
human airway epithelium was analyzed at three selected peptide concentrations by measuring the transepithelial 
electrical resistance (TEER) in polarized human primary bronchial cells. Furthermore, the human cathelicidin 
AMP LL-37 was used as a reference. As shown in Fig. 1, when all peptides were used at a concentration corre-
sponding to 2 × MIC (8 μM), they did not affect the epithelium integrity. When tested at a higher concentra-
tion (i.e. 20 μM), LL-37 initially decreased TEER, but this value recovered and was close to the initial one after 
10 hours. Differently, when used at the higher concentration of 64 μM, it exhibited significantly detrimental effect 
on disturbing the epithelial cell tight junction and its negative effect persisted for a long period of time (up-trian-
gle, broken line). In comparison, only a mild decrease in the TEER was observed for 64 μM of Esc(1–21) within 
24 h (upside down triangle, broken line). Interestingly, Esc(1-21)-1c treatment had no measureable difference on 
TEER and did not disturb the membrane integrity at the same 64 μM concentration (square).
Effect of peptides on the lung inflammatory response and pulmonary toxicity. Prior to ana-
lyzing the in vivo antipseudomonal efficacy of exogenous AMPs, the ability of the selected peptides [i.e. Esc(1–
21), Esc(1–21)-1c and LL-37] to elicit host immune response and eventually lead to pulmonary toxicity upon 
intra-tracheal delivery, was evaluated at 24 hours after their administration. The peptides were tested at a concen-
tration of 20 μM (2 μg/mouse) and 64 μM (7 μg/mouse).
Based on the concentrations used for determining the epithelial membrane permeability (Fig. 1), 64 μM (7 
μg/mouse, 0.35 mg/kg) of both Esc(1–21) and LL-37 stimulated the host immune system, causing a considerable 
increase in the number of neutrophils and macrophages in the bronchoalveolar lavage (BAL) compared to the 
amount found in the control animals receiving the vehicle phosphate buffered saline (PBS) (Fig. 2a, red bars). 
However, the lung inflammatory reaction was negligible when the peptides were used at 20 μM (2 μg/mouse, 
0.1 mg/kg), as demonstrated by the invariant number of total immune cells in the BAL compared to PBS-treated 
mice (Fig. 2b). In parallel, no observable effects on inflammation-related genes expression (such as those encod-
ing for the cytokines IL-6, IL-10 or the tumor necrosis factor-α TNFα, and NF-kB) were observed in the lungs of 
mice, at 24 hours after peptide treatment at a concentration of 0.1 mg/kg (Fig. 3a).
Furthermore, no detectable pulmonary toxicity was recorded for all peptides tested. In support of this, air-
way epithelial cell-associated genes expression including Foxj1 (ciliated cells) and Muc5b (mucous cells), having 
important roles in the lung mucociliary clearance37, was minimally affected (Fig. 3b).
Antimicrobial efficacy at 6 hours after bacterial infection. Since no unwanted harmful action at the 
lung level was pointed out when all the selected AMPs were administered at 0.1 mg/kg, their in vivo efficacy 
in treating P. aeruginosa-induced respiratory infection was then examined using a mouse model of acute lung 
infection. The peptides were intra-tracheally administered at 2 hours after bacterial challenge and the number 
of colony forming units (CFUs) in lung, BAL, and spleen was determined at 6 hours after bacterial instillation. 
As indicated in Fig. 4a, the total lung burden as shown in number of CFU (lung homogenate + BAL) was signif-
icantly reduced (90% reduction) after AMP treatment, compared to the number found in control animals that 
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were infected but received only the vehicle PBS (red bars). Overall, Esc(1–21)-1c revealed to be the peptide with 
the best in vivo antimicrobial efficacy, probably due to its longer biostability29. In addition, the significant lower-
ing in the number of bacteria in the spleen of Esc(1–21)-1c-treated mice compared to that of control animals or 
those treated with Esc(1–21) or LL-37 (Fig. 4a) indicated a substantial reduction in the systemic dissemination 
of bacterial cells and spread of infection. In parallel, the total number of leukocytes in the infected mouse lungs 
after AMPs treatment was investigated. As reported in Fig. 4b, in line with the diminished bacterial burden pro-
voked by all peptides, a lower number of immune cells, especially neutrophils, was counted in comparison with 
PBS-treated infected animals, 4 hours after peptide instillation (e.g. 6 hours from infection).
Antimicrobial efficacy at 24 hours after infection with a single or double AMP administration. 
Subsequently, the in vivo antipseudomonal activity of the diastereomer was further evaluated after a longer-term 
treatment (i.e. 24 hours from the bacterial administration). Excitingly, in this case a more noticeable antibacterial 
effectiveness than that from 4 hours AMP treatment was observed, with approximately 2-log reduction in the lung 
bacterial burden compared to the control PBS-treated infected mice (Fig. 5a). Interestingly, a second instillation 
of the diastereomer (0.1 mg/kg) at 12 hours after bacterial inoculation did not further enhance the therapeutic 
efficacy against P. aeruginosa-induced respiratory infection. Similarly, the second administration of this AMP did 
not further decrease the infection level of the spleen (Fig. 5a).
Importantly, the efficacy of Esc(1–21)-1c in reducing lung bacterial burden at 24 hours after Pseudomonas 
challenge revealed to be comparable (about 2-log reduction of lung burden) to that found for the last resort 
of antibiotics, i.e. colistin, in another set of experiments (Fig. 5b). In comparison, the human LL-37 almost 
completely lost its antimicrobial potency (Fig. 5b), presumably due to its higher susceptibility to proteolytic 
degradation29.
Figure 1. Effects of AMPs on the TEER of lung epithelial cells. Peptides in PBS were added to the apical 
compartment of the normal primary human bronchial epithelial cells maintained in ALI condition. TEER was 
measured at multiple time points (1, 2, 3, 5, 8, 10, 12 and 24 hours). Results are representative data from three 
independent experiments.
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Effect of Esc(1–21)-1c on the number of inflammatory cells in the BAL at 24 hours after infection. 
In consistence with the described results of significantly lower bacterial burden in the lungs after treatment with 
Esc(1–21)-1c, a substantial decrease in the total number of inflammatory cells was also recorded in the BAL of 
infected mice after a longer-term treatment with a single or double dosage of the diastereomer (at 0.1 mg/kg) 
compared to the control infected animals receiving the vehicle PBS only (Fig. 5c).
The therapeutic efficacy of the diastereomer closely correlated with the diminished number of inflammatory 
cells in the BAL of the animals, even though the percentage of macrophages was slightly higher than that of con-
trols. This very low percentage of macrophages within the total leukocytes presumably reflected the lower amount 
of bacterial burden and the minimally recruited neutrophils to the site of infection.
Pulmonary inflammation of infected lungs after treatment with Esc(1–21)-1c. Compared to 
infected mice treated with PBS, a marked reduction in the expression level of pro-inflammatory chemokines 
(e.g. CXCL-1, CXCL-2), cytokines (i.e. IL-6 and IL-17), and other inflammatory-related genes (Tnf-α, Nf-κb) 
was detected in the lungs of mice at 24 hours after treatment with a single or a double dosage of Esc(1–21)-1c at 
0.1 mg/kg (Fig. 6a). Indeed, the gene-expression level was similar to that of untreated non-infected mice (control, 
Fig. 6a). This suggests that therapeutic treatments with the diastereomer led to a substantially attenuated inflam-
matory response upon P. aeruginosa-induced respiratory infection. Furthermore, bacterial infection resulted in 
noticeable induction of airway epithelial gene Ccsp but only mild changes in Pseudomonas-induced lung infec-
tion, after administration of Esc(1–21)-1c (Fig. 6b). Ccsp gene encodes for Clara/Club cell secretory protein, 
and serves as a marker for assessing the cellular integrity and permeability of the lung epithelium that could be 
induced after epithelial injury38. Our results clearly supported that bacterial infection-induced lung injury was 
significantly less after one or two dosage of Esc(1–21)-1c administration. The gene expression difference in foxj1 
among various treatments was not significant.
The efficacy of Esc(1–21)-1c in alleviating respiratory Pseudomonal infection was further assessed by mouse 
lung histopathological evaluation. We observed the increased number of inflammatory cells after Pseudomonas 
infection in both airways and alveolar regions, but the increase was more prominent in the alveolar region 
(Fig. 7). There was clearly more neutrophilic infiltration in the alveoli of PBS-treated mice than in AMP-treated 
mice at 24 hours after infection (Fig. 7).
Discussion
Respiratory infection is the most common lung disease, especially in CF sufferers39, 40 and P. aeruginosa is the 
most predominant lung pathogen in the CF population where it drives to progressive loss of respiratory functions 
and shortened survival of these patients. This is mainly due to its increasing resistance to the available antibiotics 
and adaptation within the lung environment, favoring persistence and chronic lung colonization by P. aerugi-
nosa41, 42.
AMPs hold promise to act as lead compounds for the generation of novel therapeutic agents with fast and wide 
spectrum of activity, low capacity to induce resistance while displaying relevant immunomodulatory functions 
(e.g. LPS detoxification; wound-healing). However, a lot of AMPs loss their antimicrobial activity in biological 
environments and only a limited number of studies have been carried out to demonstrate the in vivo effect(s) of 
AMPs or derivatives in animal models of P. aeruginosa-induced lung infection.
Figure 2. Effect of Esc(1–21), Esc(1–21)-1c and LL37 on the number of lung inflammatory cells in mice. The 
number of macrophages, neutrophils and total inflammatory cells in the BAL of mice was counted at 24 hours 
after peptide administration at 7 μg/mouse (0.35 mg/kg) (panel a) or 2 μg/mouse (0.1 mg/kg) (panel b). Results 
are mean ± SEM from three independent experiments; n = 4–6 mice for each group in each experiment. 
Following one-way analysis of variance (ANOVA), posthoc comparisons were made using the Dunnett’s 
multiple comparison test when the P-value was significant (p < 0.05). *p < 0.05, **p < 0.01, for peptide-treated 
mice versus PBS-receiving animals.
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We previously proved that by changing the configuration of only two amino acids in Esc(1–21), with the 
corresponding d-enantiomers, the resulting diastereomer Esc(1–21)-1c had a (i) significantly higher biostabil-
ity, (ii) lower cytotoxicity, (iii) better antibiofilm activity, (iv) stronger ability in killing Pseudomonas internal-
ized into bronchial cells expressing a copy of functional or mutated CF-transmembrane conductance regulator 
(AF508 CFTR) and (v) a more pronounced wound-healing activity in monolayers of epithelial cells29. All these 
findings contributed to make Esc(1–21)-1c a very attractive candidate for the development of new drugs against 
Pseudomonas-induced lung infections. Nevertheless, no evidences on its in vivo antimicrobial efficacy were 
Figure 3. Comparison among Esc(1–21), Esc(1–21)-1c and LL-37 on the in vivo gene expression in the lungs of 
mice. Effects of peptides on the expression of different inflammatory genes (panel a) or mucociliary-associated 
genes (panel b) in the lungs of mice after 24 hours from peptide administration at 0.1 mg/kg. AMPs treatments 
at 0.1 mg/kg do not noticeably affect the expression of inflammation and mucociliary clearance-related genes. 
Results are mean ± SEM from two independent experiments; n = 4–6 mice for each group in each experiment.
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Figure 4. Comparison among Esc(1–21), Esc(1–21)-1c and LL-37 on the number of viable P. aeruginosa cells 
(CFU). CFU in mouse lungs (Total = lung homogenate + BAL) and spleens (panel a) as well as on the number 
of inflammatory cells in the BAL (panel b) of pulmonary-infected mice at 4 hours after peptide administration 
at 0.1 mg/kg were enumerated. Animals were intra-tracheally infected with 3 million PAO1 cells. The peptides 
were administered intra-tracheally, at 2 μg (0.1 mg/kg) at 2 hours after bacterial infection. The number of 
viable Pseudomonas cells in the lung and spleen as well as the number of inflammatory cells in the BAL were 
evaluated 6 hours after infection, as described in the Experimental section. Results are mean ± SEM from three 
independent experiments; n = 4–6 mice for each treatment group. Following one-way analysis of variance 
(ANOVA), posthoc comparisons were made using the Dunnett’s multiple comparison test when the P-value was 
significant (p < 0.05). *p < 0.05, **p < 0.01, ***p < 0.001 for peptide-treated animals versus PBS-treated mice.
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previously reported. Here, for the first time we demonstrated a remarkable in vivo antipseudomonal activity of 
the diastereomer Esc(1–21)-1c after a single local instillation in the lungs, with a higher potency than the all-L 
parent peptide and the widely used and characterized human AMP LL-37. Our in vivo studies underlined that 
4 hours peptide treatment is not an ideal time for an optimal evaluation of the in vivo antimicrobial effectiveness 
of esculentin-derived AMPs, which presumably relies on a direct bactericidal activity of the peptide. However, at 
this stage we cannot exclude that the respiratory epithelial cell-mediated immune modulation could also contrib-
ute to the overall host antimicrobial activity. The bacterial killing activity by Esc(1–21) and Esc(1–21)-1c would 
prevent inhaled/inoculated bacteria from propagate in mouse lung. Nonetheless, the bacterial infection-induced 
host innate immunity may be able to provide additional killing mechanism to control the severity of bacterial 
infection and to reduce inflammatory response. Importantly, we have found out that a single intra-tracheal 
instillation of Esc(1–21)-1c, at a very low peptide dosage i.e. 20 μM (0.1 mg/kg), is sufficient to cause approx-
imately 2-log reduction in the lung Pseudomonas burden, within 24 hours from bacterial challenge. The data 
suggest that the diastereomer Esc(1–21)-1c likely has a sustained residence time in the lungs, due to its higher 
biostability and resistance to proteolytic degradation than Esc(1–21) and LL-37, according to our previously 
published data28, 29. Thus, it would continue to display microbicidal effects at longer-term. In comparison, the 
in vivo antipseudomonal activity of Esc(1–21)-1c resulted to be similar in bacterial reduction to that of colistin, 
which is extensively used in clinical practice43. Note however that colistin is a peptide which is active only against 
Gram-negative bacteria and it easily induces microbial resistance31, 44, 45, most likely because of modifications to 
the phosphate groups of lipid A and core oligosaccharide moieties of LPS, weakening colistin binding to it. Yet, 
colistin resistance in humans without prior exposure to this peptide has been recently disclosed; and this is an 
important concern to public health46.
Differently, the in vivo antibacterial efficacy of LL-37 was mostly lost at longer-term (Fig. 5b), probably 
due to its higher susceptibility to proteases29. This is in contrast with previous findings by Beagumont and col-
leagues showing that in a murine model of acute P. aeruginosa lung infection, LL-37 enhanced bacterial clear-
ance in vivo only over 24 hours, by means of neutrophils recruitment, while no effect was obtained 6 hours after 
Figure 5. Effect of single or double administration of Esc(1–21)-1c (panel a); LL-37 and colistin (panel b) on 
the number of viable P. aeruginosa. The effect of single or double dosage of Esc(1–21)-1c on total leukocytes 
was also investigated (panel c). Bacterial burden (CFU) in the lung and spleen of infected mice was determined 
at 24 hours after bacterial infection. Animals were intra-tracheally infected with PAO1 cells. The peptides were 
instilled intra-tracheally, at 2 μg (0.1 mg/kg) at 2 hours (for single administration) and at 2 hours and 12 hours 
(for double administration) after bacterial infection. The numbers of viable Pseudomonas cells in the lung and 
spleen as well as the number of inflammatory cells in the BAL were counted at 24 hours after the infection, 
as described above. Results are mean ± SEM from three independent experiments; n = 4–6 mice for each 
treatment group. Following one-way analysis of variance (ANOVA), posthoc comparisons were made using 
the Dunnett’s multiple comparison test when the P-value was significant (p < 0.05). *p < 0.05, **p < 0.01 for 
peptide-treated animals versus PBS-treated mice.
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Figure 6. Effect of Esc(1–21)-1c on the expression level of different inflammatory-related genes (panel a) 
and airway epithelial-associated genes (panel b). Gene expression in the lungs of P. aeruginosa infected mice 
after a single or a double peptide administration (at 0.1 mg/kg) was investigated at 24 hours after bacterial 
infection. Mice were intra-tracheally infected with 3 million PAO1 cells. The peptides were administered intra-
tracheally at 2 μg (0.1 mg/kg) at 2 hours and 12 hours after the infection. After 24 hours from bacterial challenge, 
the RNA was extracted from the lung tissue and quantitative PCR was performed as described54. Results are 
mean ± SEM from three independent experiments; n = 4–6 mice for each treatment group. The t-test was used 
to compare the means of PBS-receiving non-infected mice (control) versus PBS-treated infected animals. One-
way analysis of variance (ANOVA) was used peptide-treated infected mice and PBS-treated infected animals, 
posthoc comparisons were made using the Dunnett’s multiple comparison test when the P-value was significant 
(p < 0.05). *p < 0.05, **p < 0.01, ***p < 0.001 for peptide-treated infected mice or PBS-receiving non-infected 
mice (control) versus PBS-treated infected animals.
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infection47. However, in their work, bacteria and peptide were co-administered via intranasal instillation rather 
than intra-tracheally. This latter administration route provides a more direct introduction of bacteria into the 
lungs and a more reproducible infection that can be more representative of pneumonia, generally leading to 
establishment of infection in the lower regions of the lungs48. In addition, intra-tracheal administration of a drug 
better mimics an aerosol-based therapy. Furthermore, immediate administration of LL-37 following bacterial 
inoculation as used in the paper47 did not allow sufficient time for the bacteria to adapt to the lung microenviron-
ment before being exposed to LL-37. Note that this previously used experimental procedure could not provide a 
valuable indication of the antimicrobial effectiveness of AMPs in vivo. Thus, in this study, we purposely delayed 
the AMP administration at 2 hours after bacterial infection to better reflect the real life infectious conditions.
Finally in our hands, LL-37 negatively disturbed bronchial epithelial cell tight junction (Fig. 1). This could 
potentially result in elevated cytotoxicity to the lung epithelial cells and limit its practical use in exogenously 
supplying viable therapy for lung bacterial infection.
To the best of our knowledge, no indication on the effect of AMPs on the expression of airway 
epithelia-associated genes upon their administration to infected or non-infected lungs has been provided so far. 
This is a fundamental issue that deserves to be investigated in order to explore the clinical safety of a new drug. 
Indeed, besides experiencing the AMPs effect on the bacterial clearance, it is also meaningful to get insight into 
their potential beneficial/toxic effect on the lung epithelium, in vivo.
Our findings have emphasized that two amino acids substitution in Esc(1–21) with the corresponding 
d-enantiomers can reduce the peptide’s cytotoxicity and withstand the feasibility of using the diasteremer to 
alleviate pneumonia severity. Furthermore, we have also shown that in addition to having a therapeutic outcome, 
the diastereomer does not induce any undesirable side effect at the lung, but it is able to abate the inflammatory 
response upon bacterial infection, as corroborated by the results of immune cell differential counts, gene expres-
sion and lung histology analysis.
In summary, the results of our work suggest a strong therapeutic potential of diastereomer Esc(1–21)-1c in 
treating bacterial infection and concur to support further advanced preclinical studies aimed at developing it 
Figure 7. Histologic analysis of lung tissues with PAO1 challenge at 24 hours after bacterial infection. Mouse 
lung tissues were harvested, fixed and stained for histological evaluation without peptide treatment (B) or with 
a single (C) and double (D) administration of Esc(1–21)-1c at 0.1 mg/kg in comparison with non-infected and 
untreated samples. (A) Infected but untreated mice (B) exhibited more inflammation, airway lumen leukocyte 
accumulation (black arrow).
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as a viable lead compound for the manufacture of new peptide-based formulation(s) for topical treatment of 
Pseudomonas lung infection.
Methods
Materials and chemicals. Synthetic Esc(1–21) and its diastereomer Esc(1–21)-1c (Table 1) were purchased 
from Chematek Spa (Milan, Italy). Briefly, each peptide was assembled by step-wise solid-phase synthesis using a 
standard F-moc strategy and purified via RP-HPLC to a purity of 98%, while the molecular mass was verified by mass 
spectrometry. Colistin sulphate was purchased from Sigma (St. Louis, MO) and the natural AMP human cathelicidin 
LL-37 (Table 1) was synthesized by Genscript (Piscataway, NJ). BronchialLife Epithelial Airway Medium was pur-
chased from Lifeline Technology (Frederick, MD). B-ALI Bronchial Air Liquid Interface BulletKit was purchased 
from Lonza (Walkersville, MD). Eagle’s minimum essential medium (EMEM), was purchased from Sigma (St. Louis, 
MO), and tryptic soy broth (TSB) and trypitc soy agar (TSA) were purchased from MP Biomedicals (Santa Ana, CA).
Bacteria. The Pseudomonas aeruginosa strain (PAO1, ATCC BAA-47) was used for all the experiments. For each 
experiment, an aliquot of bacteria was grown overnight at 37 °C in TSB with shaking at 225 rpm to achieve a stationary 
phase suspension. Afterwards, an aliquot was diluted 1:5 into fresh TSB and incubated at 37 °C for additional 2 h at 
37 °C to reach an exponential growth phase. Bacterial cells were harvested by centrifugation at 1,500 × g for 10 min, 
washed twice and resuspended in PBS to adjust the concentration at 6 × 107 CFU/ml, for use in the experiments.
Primary bronchial epithelial cells. Fully differentiated primary human bronchial epithelial (HBE) cell 
cultures were derived from lungs removed at the time of lung transplantation from the Center for Organ Recovery 
and Education. Cells were prepared using previously described methods approved by the University of Pittsburgh 
IRB49, 50. Briefly, bronchi from the 2nd to 6th generations were collected, rinsed, and incubated overnight in 
EMEM at 4 °C. The bronchi were then digested in MEM containing protease XIV and DNase (0.2%). The epi-
thelial cells were removed and collected by centrifugation and then resuspended in BronchiaLife medium and 
plated onto collagen-treated tissue culture flasks. When 80–90% confluence was reached, the passage 0 cells were 
trypsinized and seeded onto collagen-coated transwell permeable supports (Corning #3450, 105 cells/well). B-ALI 
Bronchial Air Liquid Interface Medium was replaced three times a week on both apical and basolateal sides of 
the permeable supports up to 8–10 days. Subsequently the apical medium was removed and the cultures were 
maintained at air liquid interface (ALI) to promote a further polarization and differentiation of the epithelium. 
The basolateral medium was changed twice weekly.
Animals. Wild-type C57BL/6J female mice were purchased from Jackson Laboratory (Bar Harbor, ME) 
and maintained in a specific pathogen-free status in a 12 hours light/dark cycle. All procedures were conducted 
using mice 6–8 weeks of age maintained in ventilated microisolator cages housed in an American Association 
for Accreditation of Laboratory Animal Care (AAALAC) approved animal housing facility. Protocols and studies 
involving animals were conducted in accordance with National Institutes of Health guidelines and approved by 
the Institutional Animal Care and Use Committee (IACUC) at the University of Pittsburgh.
Lung epithelium permeability. Lung epithelial integrity in polarized primary bronchial cells was exam-
ined by measuring the TEER using an electronic resistance system (Millicell ERS-2, EMD Millipore). Ex 
vivo-differentiated lung epithelium was grown on ALI in 24-transwell plates (Corning, Tewksbury, MA) using 
BronchiaLife Epithelial Airway Medium in the basolateral compartment. Peptides dissolved in PBS at different con-
centrations were added onto the apical surface of the differentiated epithelial cells in a final volume of 100 μl. A sterile 
electrode was applied onto the apical side of the transwell insert containing the cultured epithelial cells with/without 
peptide treatments and the electrical resistance was measured three times for comparison at different time intervals.
Bronchoalveolar lavage and differential cell counts. Mice were anesthetized with inhalation of iso-
flurane and the peptide was intra-tracheally administered in 50 µl of PBS at 20 μM and 64 μM corresponding to a 
peptide dosage of 0.1 mg/kg and 0.35 mg/kg, respectively. Control mice were instilled with 50 µl of PBS without 
peptide. After 24 hours of treatment, mice were anesthetized with 2.5% tribromoethanol (Avertin). The trachea 
was cannulated, the lungs were lavaged twice using 1 ml saline, and the BAL samples collected as previously 
described51. The number of live immune cells in the BAL was determined by a Vision Cell Analyzer automatic 
cell counter (Nexcelom, Lawrence, MA). An additional aliquot was placed onto glass microscope slides (Shanon 
Cytospin; Thermo Fisher, Pittsburgh, PA), stained with Diff-Quick (Thermo Fisher Scientific, Waltham, MA); 
cell differential was determined microscopically. A total of 400 cells of every slide were counted at least twice 
independently for inflammatory cell differential counts. In other sets of experiments, cell differential counts were 
evaluated in the BAL of infected mice treated with or without peptides at 6 hours or 24 hours after peptide admin-
istration, as indicated.
Peptide Primary structurea
Esc(1–21) GIFSKLAGKKIKNLLISGLKG-NH2
Esc(1–21)-1c GIFSKLAGKKIKNLLISGLKG-NH2
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Table 1. Primary structure of the peptides under study. ad-amino acids are in italics and bolded.
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Murine infection model. Mice were anesthetized with inhalation of isoflurane and instilled with PAO1 
bacteria (sensitive to all peptides), through intra-tracheal inoculation of ~3 × 106 CFU per mouse in 50 µl PBS. 
Two hours after the bacterial infection, the peptide was intra-tracheally administered at desired dosage in 50 µl of 
PBS. Control mice were instilled with 50 µl of PBS without peptide. For repeated dosage experiments, the peptide 
was intra-tracheally instilled at 2 hours and 12 hours after bacterial infection.
Determination of bacterial burden. After 6 hours or 24 hours of bacterial instillation, the numbers of 
CFU in lungs, BAL and spleen were determined by serial dilution on TSB agar plates. Mice (5–6 mice/group) 
were anesthetized with 2.5% tribromoethanol. The trachea was cannulated, the lungs were lavaged twice using 
1 ml saline, and the BAL samples collected. The left lung lobe was homogenized in 1 ml saline and placed on ice. 
Dilution of 100 μl of lung tissue homogenate or BAL was mixed with 900 μl PBS. Four serial 10-fold dilutions 
in saline were prepared and plated on TSB agar plates and incubated overnight at 37 °C, each dilution plated in 
triplicate, for counting.
Gene expression analysis by quantitative real-time PCR. The peptides’ effect on the expression of 
different inflammatory genes or airway epithelial cells-related genes after peptide administration at 0.1 mg/kg to 
non-infected or infected mice was determined, as indicated. Briefly, total mRNA was isolated from the right lung 
tissues using Trizol reagent. Quantitative PCR was performed using ABI 7900HT (Applied Biosystems, Foster 
City, CA) and primers of all genes tested including IL-6, IL-10, Tnf-α, Nf-κb, Muc5b, Foxj1. Validation tests 
were performed to confirm equivalent PCR efficiencies for the target genes. Test and calibrator lung RNAs were 
reverse transcribed using a high-capacity cDNA reverse transcription kit (Life Technologies) and PCR was ampli-
fied as follows: 50 °C for 2 min, 95 °C for 10 min, 40 cycles; 95 °C for 15 s; 60 °C for 1 min. Three replicates were 
used to calculate the average cycle threshold for the transcript of interest and for a transcript for normalization 
(β-glucuronidase; Assays on Demand; Applied Biosystems). Relative mRNA abundance was calculated using the 
ΔΔ cycle threshold (Ct) method.
Lung histopathology. Lung tissues were harvested from mice at 24 hours after infection and compared with 
those without infection or after infection and peptide treatment (single or double administration at 0.1 mg/kg, 
as described above). Afterwards, they were fixed in situ with 4% paraformaldehyde for 10 minutes with the chest 
cavity open. The right lobe was embedded in paraffin and 5 μm sections were prepared. Sections were stained with 
hematoxylin and eosin, and histological evaluation was performed to examine bacterial infection-induced patho-
logical severity. The stained lung sections were evaluated in a double-blind fashion under a light microscope, as 
described previously52, 53.
Data analysis. Data are expressed as mean ± SEM. Statistical comparisons between groups of mice were 
made using ANOVA, followed by Dunnett’s multiple comparison test or Tukey–Kramer test (one way ANOVA). 
A p value < 0.05 was considered to be statistically significant.
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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